Therapeutic agents targeting the BCR signaling (like Ibrutinib, Idelalisib, and Duvelisib) or BCL2 inhibitors (Venetoclax) have dramatically changed the treatment options for CLL in the last few years [5]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.